MedTrace Logo

UK Study Assessing Flexible Dose Fesoterodine in Adults

NCT00806494 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2011-01-26

Study results available
· View outcomes & findings →

Summary

To explore the effects of fesoterodine when used in a flexible dose manner

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

Fesoterodine

Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00806494 on ClinicalTrials.gov